Immunic advances MS drug toward key Phase 3 data, expects results by year-end

Immunic Inc (NASDAQ:IMUX, FRA:10VA) is preparing for a bid of objective and firm milestones arsenic it advances its pb cause campaigner vidofludimus calcium done late-stage improvement successful aggregate sclerosis, portion expanding its enactment squad up of imaginable regulatory filings and commercialization.

The biotechnology institution reported second-quarter results connected Tuesday and said its Phase 3 ENSURE-1 and ENSURE-2 trials evaluating vidofludimus calcium successful relapsing aggregate sclerosis stay connected way to present top-line information by the extremity of 2026.

If the results are positive, Immunic plans to taxable a New Drug Application successful the US successful mid-2027, with a imaginable regulatory determination targeted for 2028.

The institution is besides preparing to statesman a Phase 3 programme evaluating vidofludimus calcium successful progressive aggregate sclerosis aboriginal this year. The planned survey follows information from the Phase 2 CALLIPER trial, including analyses presented astatine the 2026 Consortium of Multiple Sclerosis Centers yearly gathering that covered disablement progression, patient-reported outcomes, information and tolerability.

Immunic has besides made respective changes to its absorption and committee arsenic it moves toward imaginable commercialization. Erik Lundgren was appointed main enforcement serviceman successful May and joined the committee successful July, portion Michael A. Panzara became main aesculapian serviceman successful April. Michael W. Bonney was appointed seat of the committee successful May, and Elena Ridloff joined the committee successful August.

For the 2nd quarter, Immunic reported full operating expenses of $35.3 million, up from $27.0 cardinal a twelvemonth earlier.

Research and improvement expenses roseate to $25.9 cardinal from $21.3 million, with the summation chiefly reflecting higher unit expenses and drug-drug enactment studies supporting a imaginable regulatory filing.

General and administrative expenses accrued to $9.4 cardinal from $5.7 million, driven by higher personnel, ineligible and consulting costs and pre-commercial selling expenses.

The institution reported a 2nd 4th nett nonaccomplishment of astir $34.1 million, oregon $0.80 per basal and diluted share, compared with a nett nonaccomplishment of $26.8 million, oregon $2.03 per share, successful the year-earlier period. The little per-share nonaccomplishment reflected a higher weighted-average stock count.

Immunic ended the 4th with $155.1 cardinal successful currency and currency equivalents and said it expects those funds to enactment operations into precocious 2027.

Immunic CEO Erik Lundgren said the institution had continued to execute connected its late-stage improvement priorities and had strengthened its committee and absorption squad with aggregate sclerosis development, medical, regulatory and commercialization expertise.